In thrombotic antiphospholipid syndrome, DOACs vs. VKAs increase arterial thrombotic events but not major bleeding

Ann Intern Med. 2023 Apr;176(4):JC43. doi: 10.7326/J23-0016. Epub 2023 Apr 4.

Abstract

Khairani CD, Bejjani A, Piazza G, et al. Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials. J Am Coll Cardiol. 2023;81:16-30. 36328154.

Publication types

  • Meta-Analysis
  • Comment

MeSH terms

  • Administration, Oral
  • Anticoagulants / adverse effects
  • Antiphospholipid Syndrome* / complications
  • Antiphospholipid Syndrome* / drug therapy
  • Hemorrhage / chemically induced
  • Humans
  • Thrombosis* / etiology
  • Vitamin K / therapeutic use

Substances

  • Anticoagulants
  • Vitamin K